International Journal of Molecular Sciences Review The Many Facets of Metzincins and Their Endogenous Inhibitors: Perspectives on Ovarian Cancer Progression Ruth M. Escalona 1,2,3, Emily Chan 1, George Kannourakis 3,4, Jock K. Findlay 1,2 and Nuzhat Ahmed 1,2,3,4,* 1 Department of Obstetrics and Gynaecology, University of Melbourne, Parkville, VIC 3052, Australia;
[email protected] (R.M.E.);
[email protected] (E.C.); jock.fi
[email protected] (J.K.F.) 2 The Hudson Institute of Medical Research, Clayton, VIC 3168, Australia 3 Fiona Elsey Cancer Research Institute, Ballarat, VIC 3353, Australia;
[email protected] 4 Federation University Australia, Ballarat, VIC 3010, Australia * Correspondence:
[email protected]; Tel.: +61-403038387 Received: 19 December 2017; Accepted: 24 January 2018; Published: 2 February 2018 Abstract: Approximately sixty per cent of ovarian cancer patients die within the first five years of diagnosis due to recurrence associated with chemoresistance. The metzincin family of metalloproteinases is enzymes involved in matrix remodeling in response to normal physiological changes and diseased states. Recently, there has been a mounting awareness of these proteinases and their endogenous inhibitors, the tissue inhibitors of metalloproteinases (TIMPs), as superb modulators of cellular communication and signaling regulating key biological processes in cancer progression. This review investigates the role of metzincins and their inhibitors in ovarian cancer. We propose that understanding the metzincins and TIMP biology in ovarian cancer may provide valuable insights in combating ovarian cancer progression and chemoresistance-mediated recurrence in patients. Keywords: metzincins; ovarian cancer; metastasis; matrix metalloproteinases (MMPs); disintegrin and metalloproteinases (ADAMs); ADAM proteases with thrombospondin motifs (ADAMTS); TIMPs 1.